New advances in targeted therapy and immunotherapy of acute myelogenous leukemia
10.3760/cma.j.issn.1009-9921.2020.01.003
- VernacularTitle: 急性髓系白血病靶向治疗和免疫治疗新进展
- Author:
Ruihua MI
1
;
Lin CHEN
1
;
Xudong WEI
1
Author Information
1. Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
- Publication Type:Review
- Keywords:
Leukemia, myelogenous, acute;
Immunotherapy;
Gene change;
Molecular targeted therapy
- From:
Journal of Leukemia & Lymphoma
2020;29(1):9-16
- CountryChina
- Language:Chinese
-
Abstract:
Acute myelogenous leukemia (AML) is a highly heterogeneous malignant hematologic disease, and it is mainly treated with traditional chemotherapy, but the efficacy is limited and the patients with worse performance status and comorbidities can not be treated with chemotherapy. Gene changes play an important role in the diagnosis and prognosis of AML, and these gene changes also provide targets for molecular targeted therapy. Meanwhlie, immunotherapy has achieved certain curative effects in AML and has a promising prospect. In this review, targeted therapy and immunotherapy of AML reported in 61st American Society of Hematology (ASH) Annual Meeting are summarized.
